Pharmaceutical Executive-10-01-2014

New research on the role of microbes in fighting disease is transforming the way medicine views bacteria, writes Lee Jones.

Pharmaceutical Executive

Is crowdfunding an attractive alternative to finance pharma and biotech start-ups? Seth R. Ogden and M. Andrew Holtman report.

Pharmaceutical Executive
Column

October 01, 2014

Companies gain support-and pressure-to deliver new treatments for spreading outbreak.

Pharmaceutical Executive

Pharmaceutical professionals, teams, and organizations can succeed at an elite level by tackling the tough mental challenges of Navy SEAL training.

Pharmaceutical Executive

An escalating political debate over pharma pricing and reimbursement nears the boiling point.

Pharmaceutical Executive
Column

October 01, 2014

Inter Partes Review can potentially offer a more economical and streamlined litigation strategy for pharma and biotech players, writes David Dalke.

Pharmaceutical Executive

NICE's David Haslam discusses the UK drug watchdog's new challenge in meeting expectations around what quantitative calculations of value mean to patient access today.

Pharmaceutical Executive

Amid the continued surge in M&A activity, Michael Swanick asks, what are the crucial considerations pharma executives should weigh before sitting down at the deals table?